Bluebird Bio Receives a Buy from Jefferies

By Carrie Williams

Jefferies analyst Gena Wang reiterated a Buy rating on Bluebird Bio (NASDAQ: BLUE) yesterday and set a price target of $80. The company’s shares closed yesterday at $62.50.

According to, Wang is ranked 0 out of 5 stars with an average return of -15.5% and a 34.7% success rate. Wang covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Cascadian Therapeutics, and Atara Biotherapeutics.

Currently, the analyst consensus on Bluebird Bio is Strong Buy and the average price target is $90.40, representing a 44.6% upside.

In a report released yesterday, Janney Montgomery also reiterated a Buy rating on the stock.

Based on Bluebird Bio’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.55 million and GAAP net loss of $77.03 million. In comparison, last year the company earned revenue of $1.32 million and had a GAAP net loss of $42.92 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLUE in relation to earlier this year. Most recently, in June 2016, Nick Leschly, the President & CEO of BLUE bought 19,826 shares for a total of $76,173.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company develops next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. It has two clinical-stage programs in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease and a preclinical oncology program in the chimeric antigen receptor T cells field. bluebird bio was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.